Novartis gets approval for Coartem Baby, first malaria treatment for infants under 4.5 kg.

Novartis has received approval for Coartem Baby, the first malaria treatment for newborns and young infants, from Swissmedic. Developed with Medicines for Malaria Venture (MMV), this dissolvable, cherry-flavored treatment addresses the lack of approved malaria medicines for infants under 4.5 kilograms. The drug will be introduced on a largely not-for-profit basis, with rapid approvals expected in eight African countries. This breakthrough aims to increase access to treatment in malaria-endemic regions, especially in Africa.